Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Spatial Corp. and Kawasaki Heavy Industries, Ltd Collaborate to Leverage Spatial Software Components to Power neoROSET Robot Programming19.3.2025 00:00:00 EET | Press release
Spatial Corp., the leading 3D software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, and Kawasaki Heavy Industries, Ltd today announced their collaboration to leverage Spatial Software Development Kits (SDKs) in the development of neoROSET, Kawasaki next-generation offline robot programming tool. With Spatial, Kawasaki Heavy Industries, Ltd. benefited from SDK technological excellence as well as expertise to develop neoROSET, its advanced industrial robot programming software designed to simplify and optimize robotic systems assessment and construction. Key Spatial SDKs used in neoROSET include: CGM Modeler, a state-of-the-art 3D modeling kernel 3D InterOp, a robust data translation library enabling seamless data import and export in major formats HOOPS Visualize, a high-performance graphics library offering state-of-the-art visualization capabilities for engineering applications AGM, a comprehensive 3D applicati
NetApp Storage Now Validated for NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Systems18.3.2025 22:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NVIDIA has validated high-performance NetApp enterprise storage systems with NetApp ONTAP® for environments powering AI training and inferencing. For the first time, with NetApp, customers can now get the benefits of validated configurations and architectures for NVIDIA—including NVIDIA DGX SuperPOD, NVIDIA Cloud Partners, and NVIDIA-Certified Storage—combined with the rich and mature data management services in NetApp ONTAP critical for building AI factories. These certifications ready NetApp to tap the NVIDIA AI Data Platform reference design for NetApp ONTAP to advance storage infrastructure with AI agents for reasoning model inference workloads, powered by NVIDIA accelerated computing, networking, and software. “NetApp and NVIDIA are longstanding technology partners, jointly serving hundreds of customers for AI model training and inferencing,” said Jonsi Stefansson, Senior Vice President and C
NetApp Fuels Future of Agentic AI Reasoning Solutions with NVIDIA AI Data Platform18.3.2025 22:00:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it is advancing the state of the art in agentic AI with intelligent data infrastructure that taps the NVIDIA AI Data Platform reference design. By collaborating with NVIDIA, NetApp is enabling businesses to better leverage their data to fuel AI reasoning inference. In the era of intelligence, businesses need to rethink their data strategies to turn rapidly growing data estates into competitive assets that empower them to agilely navigate their business environment. By adopting an Intelligent Data Infrastructure framework, businesses will be able to operate under a unified vision that integrates metadata cataloging, automation, and hybrid cloud capabilities to eliminate siloes and deliver actionable insights at every stage of the AI pipeline. Together, NetApp ONTAP® and the NVIDIA AI Data Platform enable businesses to navigate the era of intelligence by building distributed systems that unlock the full
Outseer Launches Platformized Behavioral Biometrics Delivering Unmatched Defense in Depth18.3.2025 21:52:00 EET | Press release
Outseer, a recognized leader in authentication and fraud prevention for digital banking and 3-D Secure (3DS) transactions, announced its platform-native Behavioral Biometrics capability today. The addition of platformized Behavioral Biometrics introduces another layer of defense that continuously analyzes user interactions to detect anomalies in real time. Building on its rich RSA® heritage (formerly RSA Fraud & Risk Intelligence™), Outseer has enhanced its platform to meet today’s dynamic threat landscape. As fraud evolves—spurred by the digitization of payments, the spread of personal data across the dark web, the growing threat of scams and authorized fraud, as well as advancements like GenAI—Outseer’s multi-signal risk engine, leveraging sophisticated machine learning algorithms and AI, sets a new standard for continuous, unified protection. “Our customers are facing rising authorized and unauthorized fraud threats in digital banking and 3DS transactions, requiring fraud solutions
Ravenna Becomes the First Colourblind-Friendly City in Italy: Event and New EnChroma Glasses Donation18.3.2025 18:29:00 EET | Press release
Tomorrow, March 19, 2025, at 4:30 PM, the conference "How Colourblind People See" will be held at the Martini Hall of MAR – Ravenna’s Museum of Art. This event is dedicated to raising awareness about colour blindness and the challenges of colour perception. Speakers will include Stefano De Pietro, President of the Italian Association "How Colourblind People See", and Sandor Breznay, President of the Breznay-Ganoczy Foundation (Agno, Switzerland) and the Paolina Brugnatelli Foundation (Milan). Colour blindness affects approximately 1 in 12 men and 1 in 200 women, with over 300 million people worldwide experiencing this condition—2.5 million in Italy. While those with normal colour vision can distinguish over a million shades, individuals with colour vision deficiency see only about 10% of those hues. As a result, colours may appear dull or even indistinguishable. This initiative aims to increase public awareness and make cultural and educational experiences more accessible for those wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom